~~<i id='68EF760498'><strike id='68EF760498'><tt id='68EF760498'><pre id='68EF760498'></pre></tt></strike></i>~~

Home» comprehensive» comprehensive

comprehensive

author：leisure time 2025-09-13 16:57:06 Page View：92249

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： In age of alternative facts, a scholarly course on calling out crap

comprehensive

Dobbs anniversary: the lost opportunity of abortion as health care

NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

HIV drugs protect against transmission, even in unprotected sex

JoeRaedle/GettyImagesCouplesinwhichonepartnerisHIV-positivehavealowriskoftransmittingthediseaseifthe

Wildfire smoke exposes gaps in outdoor worker protections

ApersonwaitingforthesubwaywearsafilteredmaskassmokyhazefromwildfiresinCanadablanketsaneighborhoodinN

How to increase colonoscopy rates? Looks like an AI can help

AdobeCHICAGO—Peoplecanbemightilyreluctanttogetacolonoscopyforreasonslikecost,languagebarriers,orfear